{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:38:15Z","timestamp":1765521495021,"version":"3.48.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Escitalopram (SCT), a highly effective and low-risk antidepressant, is widely used in the clinical treatment of depression. It undergoes two N-demethylation steps, producing its primary metabolites, S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to develop and validate an LC-MS\/MS method to simultaneously detect SCT, S-DCT, and S-DDCT, and then apply it to study metabolism in different microsomes, comparing SCT metabolism in rat liver microsomes (RLM), human liver microsomes (HLM), and human placenta microsomes (HPM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study developed a reliable LC-MS\/MS method for the simultaneous detection of escitalopram and its metabolites in various microsomal systems. The method was fully validated in rat liver microsomes and then was applied into human liver and placenta microsomes. The method was further applied to investigate escitalopram metabolism in different microsomal systems, notably for the first time in human placenta microsomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LC-MS\/MS method provides high specificity, good stability, and excellent extraction recovery. Both intra-day and inter-day accuracy (% RE) and precision (% RSD) were within \u00b115%, with no significant matrix effects observed. The metabolic rates of escitalopram and its metabolite levels differed among rat liver, human liver, and human placenta microsomes, likely due to variations in the types and activities of drug-metabolizing enzymes present in these systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A sensitive and reliable LC-MS\/MS method was developed and validated for the quantitative analysis of SCT, S-DCT, and S-DDCT in RLM. Subsequently, the method was applied to the study of HLM and HPM. Incubation experiments using these microsomal systems showed that all three types of microsomes, including HPM, could metabolize SCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1714686","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:31Z","timestamp":1765521271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of an LC-MS\/MS method to quantitatively analyze escitalopram and its metabolites with application in liver and placenta microsome metabolism"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifei","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenmeizi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junze","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1358\/dot.2004.40.2.799424","article-title":"Escitalopram","volume":"40","author":"Aronson","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/chromsci\/bmz073","article-title":"Application of LC-ESI-MS\/MS method for analysis of escitalopram oxalate in human urine and pharmaceutical dosage forms","volume":"58","author":"Badulla","year":"2020","journal-title":"J. Chromatogr. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1590\/s2317-17822013000200017","article-title":"Diagnostic and statistical manual of mental disorders (DSM)","volume":"25","author":"Battle","year":"2013","journal-title":"Codas"},{"key":"B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11920-016-0664-7","article-title":"Depression during pregnancy and postpartum","volume":"18","author":"Becker","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcpt.13133","article-title":"Quantitation of escitalopram and its metabolites by liquid chromatography-tandem mass spectrometry in psychiatric patients: new metabolic ratio establishment","volume":"124","author":"Canbolat","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"113763","DOI":"10.1016\/j.jpba.2020.113763","article-title":"Investigation of the content differences of arachidonic acid metabolites in a mouse model of breast cancer by using LC-MS\/MS","volume":"194","author":"Chen","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD006532","DOI":"10.1002\/14651858.CD006532.pub2","article-title":"Escitalopram versus other antidepressive agents for depression","volume":"2016","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e5237","DOI":"10.1002\/bmc.5237","article-title":"Selective LC-MS\/MS determination of citalopram enantiomers and application to a pharmacokinetic evaluation of generic and reference formulations","volume":"36","author":"de Sousa","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-014-0233-3","article-title":"Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome","volume":"54","author":"Ewing","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/j.jpba.2023.115457","article-title":"Establishment of LC-MS\/MS method for quantifying chlorpromazine metabolites with application to its metabolism in liver and placenta microsomes","volume":"233","author":"Fu","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.12116\/j.issn.1004-5619.2020.04.017","article-title":"Determination of escitalopram in biological samples by dispersive liquid-liquid microextraction combined with GC-MS\/MS","volume":"36","author":"Guan","year":"2020","journal-title":"Fa Yi Xue Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy swedes","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"114810","DOI":"10.1016\/j.jpba.2022.114810","article-title":"Development and validation of UHPLC-MS\/MS method for simultaneous quantification of escitalopram and its major metabolites in human plasma and its application in depressed patients","volume":"217","author":"Hu","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"700149","DOI":"10.3389\/fpsyt.2021.700149","article-title":"Label-free liquid chromatography-mass spectrometry proteomic analysis of the urinary proteome for measuring the escitalopram treatment response from major depressive disorder","volume":"12","author":"Huan","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122671","DOI":"10.1016\/j.jchromb.2021.122671","article-title":"Establishment of LC-MS\/MS method for determination of aloperine in rat plasma and its application in preclinical pharmacokinetics","volume":"1173","author":"Huang","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/dta.2173","article-title":"Enantioselective analysis of citalopram and demethylcitalopram in human whole blood by chiral LC-MS\/MS and application in forensic cases","volume":"9","author":"Johansen","year":"2017","journal-title":"Drug Test. Anal."},{"key":"B18","doi-asserted-by":"publisher","first-page":"117241","DOI":"10.1016\/j.bcp.2025.117241","article-title":"CYP3A mediates drug-drug interactions between atorvastatin and omeprazole: evidence from in vitro and in vivo studies","volume":"242","author":"Liang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"National Birth defects prevention study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/clpt.2009.154","article-title":"Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain","volume":"86","author":"Noehr-Jensen","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1517\/17425255.2014.863873","article-title":"Clinical pharmacology review of escitalopram for the treatment of depression","volume":"10","author":"Pastoor","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bpobgyn.2015.04.004","article-title":"Depression during pregnancy","volume":"29","author":"Pearlstein","year":"2015","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","article-title":"The clinical pharmacokinetics of escitalopram","volume":"46","author":"Rao","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/da.22670","article-title":"Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder","volume":"34","author":"Rethorst","year":"2017","journal-title":"Depress Anxiety"},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1124\/dmd.29.8.1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"B27","doi-asserted-by":"publisher","first-page":"593710","DOI":"10.3389\/fpsyt.2021.593710","article-title":"Development and internal validation of a novel model to identify inflammatory biomarkers of a response to escitalopram in patients with major depressive disorder","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:32Z","timestamp":1765521272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1714686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1714686"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1714686","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1714686"}}